KOSTLIVY, Tomas, Petr SKOPEK, Pavel KLAIL, Hana LAIEROVA, Alena SKALOVA, Břetislav GÁL, Radek KUCERA, Vaclav SIMANEK a David SLOUKA. Newborn Hearing Screening - An Implementation Analysis. In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2024, roč. 38, č. 4, s. 1939-1946. ISSN 0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.13650.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Newborn Hearing Screening - An Implementation Analysis
Autoři KOSTLIVY, Tomas (203 Česká republika), Petr SKOPEK (203 Česká republika), Pavel KLAIL (203 Česká republika), Hana LAIEROVA (203 Česká republika), Alena SKALOVA (203 Česká republika), Břetislav GÁL (203 Česká republika, domácí), Radek KUCERA (203 Česká republika), Vaclav SIMANEK (203 Česká republika) a David SLOUKA (203 Česká republika).
Vydání In vivo, ATHENS, Greece : International Institute of Anticancer Research, 2024, 0258-851X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30206 Otorhinolaryngology
Stát vydavatele Řecko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.300 v roce 2022
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.21873/invivo.13650
UT WoS 001266321000049
Klíčová slova anglicky Newborn; hearing screening; hearing loss treatment
Štítky 14110126, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 15. 8. 2024 10:22.
Anotace
Background/Aim: Hearing impairment affects a small but significant percentage of newborns (0.1-0.4%). Newborn hearing screening (NHS) is recommended for early detection and treatment. The implementation of NHS can vary among countries. In this study, we present the methodology, organization, and technical requirements of NHS. This study analyzed results from a tertiary hospital, identified issues, and proposed solutions. Patients and Methods: In the studied region, there are five maternity hospitals and a perinatal intensive care center and in 2020, there were 5,864 live births. Screening is performed at three levels. The first screening is conducted on the 2nd-3rd day of a newborn's life in a maternity hospital, the first rescreening on the 3rd-6th week at a relevant ENT department, and the second rescreening on the 3rd-6th month of life at the regional screening center where the central database is also held. Results: In the studied region, 5,793 out of 5,864 (98.79%) newborns received NHS in 2020. Of these, 120 (2.07%) were tested positive on their first screening. Ninetyfour patients (78.3%) of those attended the ENT department for a first rescreening. Thirty-four patients (0.59% of total) were tested positive again and referred to the regional screening center. Out of the 27 patients who attended the second rescreening, four (0.07% of the total) were ultimately diagnosed with hearing impairment. Conclusion: Our study found that newborn hearing screening (NHS) in our region achieved a high compliance rate of 98.8% for initial screenings in 2020. However, challenges remain in the rescreening process due to data management issues, interregional cooperation, and public awareness. The recent implementation of mandatory screenings, updated guidelines, and a centralized database is expected to enhance the effectiveness of NHS. Further research is needed to evaluate these improvements.
VytisknoutZobrazeno: 8. 9. 2024 02:20